September 3rd, 2013
A Transatlantic Taste
Amanda Ruth Vest, MBBS
A fellow wonders about worldwide differences in clinical and research approaches in cardiology, as she attends a session on a controversial area that sits uncomfortably alongside the weight-loss message central to American efforts to improve cardiovascular health.
September 2nd, 2013
Living History and a Glimpse into the Future
M. Louis Handoko, MD PhD
Louis Handoko encounters Eugene Braunwald and finds himself drawn toward electrophysiology.
September 2nd, 2013
What You See Is Not Always What You Get
Paddy Barrett, MB BCh BAO MRCPI MCTI
The COMPARE trial results prompt Paddy Barrett to wonder: Should disease criteria in clinical trials rely more on molecular than on clinical features?
September 2nd, 2013
Sharper Focus Needs a Wider View
Paddy Barrett, MB BCh BAO MRCPI MCTI
Paddy Barrett points out the paradox that to be a subspecialist, one now needs to gain a broader knowledge of other fields.
September 1st, 2013
Thank You, Dr. Messika-Zeitoun!
M. Louis Handoko, MD PhD
Louis Handoko shares his appreciation for an illuminating session on the management of asymptomatic aortic stenosis.
September 1st, 2013
A TASTE of Today and Tomorrow
Paddy Barrett, MB BCh BAO MRCPI MCTI
A fellow at ESC 2013 muses on the changes in how medical information is disseminated and accessed.
September 1st, 2013
An Almost Striking Start to ESC
Paddy Barrett, MB BCh BAO MRCPI MCTI
A fellow reports on some of the biggest presentations and most interesting finds at ESC 2013.
September 1st, 2013
A World Conference in My Backyard
M. Louis Handoko, MD PhD
A hometown fellow plunges headfirst into the 2013 ESC Congress.
September 1st, 2013
ESC.13 Headquarters
CardioExchange Editors, Staff
Find all of our ESC.13 coverage here.
September 1st, 2013
Inside the ACCOAST Trial of Pretreatment Prasugrel
Gilles Montalescot, MD, PhD, John Ryan, MD, Richard A. Lange, MD, MBA and L. David Hillis, MD
Gilles Montalescot, lead investigator of the ACCOAST trial, discusses why prasugrel pretreatment did not benefit patients with non–ST-segment elevation acute coronary syndromes.